Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Bayer’s Shares Rise Following Late-Stage Alpharadin Data

By Pharmaceutical Processing | September 27, 2011

Shares in Bayer rose nearly 4 percent Monday, two days after the company reported detailed results from a late-stage trial of its experimental prostate cancer treatment, Alpharadin (radium-223 chloride). The data showed that the agent significantly prolonged the life of patients with castration-resistant prostate cancer and symptomatic bone metastases compared to placebo. UniCredit analyst Maxwell Craig remarked that currently “Bayer is our top pick in EU pharmaceuticals.”

 

The analyst noted that with the expected launch of three drugs that could record blockbuster sales, including Alpharadin and the oral anticoagulant Xarelto (rivaroxaban), the company “has arguably the richest pharma-pipeline newsflow over the next 12 months.” The other medicine, Eylea (aflibercept), is being developed by Bayer and partner Regeneron Pharmaceuticals for various ophthalmology indications, including wet age-related macular degeneration.

 

Last week, European regulators recommended expanding approval of Xarelto to include use for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation. The European Medicines Agency also backed use of the drug for the treatment of deep vein thrombosis (DVT) and the prevention of recurrent DVT and pulmonary embolism in adults who have suffered a previous acute DVT. The product is already authorised to prevent venous blood clots in adults undergoing elective hip or knee replacement surgery.

 

Craig remarked that although Bristol-Myers Squibb and Pfizer’s similar drug Eliquis “looks very good…Xarelto will have a significant headstart, once-daily dosing [versus twice daily] and the additional venous-clot indications.”

 

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards